{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Food", "Interactions", "Medicinal plants", "Oral antineoplastic agents"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "27316629", "DateCompleted": {"Year": "2017", "Month": "02", "Day": "07"}, "DateRevised": {"Year": "2018", "Month": "11", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2016", "Month": "06", "Day": "17"}], "Language": ["eng"], "ELocationID": ["10.1007/s00432-016-2190-8"], "Journal": {"ISSN": "1432-1335", "JournalIssue": {"Volume": "142", "Issue": "11", "PubDate": {"Year": "2016", "Month": "Nov"}}, "Title": "Journal of cancer research and clinical oncology", "ISOAbbreviation": "J Cancer Res Clin Oncol"}, "ArticleTitle": "Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account.", "Pagination": {"StartPage": "2319", "EndPage": "2330", "MedlinePgn": "2319-30"}, "Abstract": {"AbstractText": ["To review interactions between oral antineoplastic agents (OAAs) for the treatment of solid and hematological tumors and common food and medicinal plants.", "All potential interactions between OAAs, medicinal plants and food were reviewed. OAAs were considered to be drugs for oral administration that have direct antitumor activity and were approved by the European Medicines Agency in April 2015. We performed the literature search in Pubmed(\u00ae) considering only medicinal plants and food. In addition, available data were analyzed from each OAA in secondary data sources taken from Thomson Micromedex(\u00ae) and Lexi-comp(\u00ae), as well as in the summary of product characteristics.", "Fifty-eight OAAs were analyzed. We found interactions in 60.3\u00a0% of OAAs. Those with most interactions described were: imatinib and procarbazine (4 interactions) and erlotinib, vemurafenib, pomalidomide, medroxyprogesterone and methotrexate (3 interactions).", "We found 39 interactions (74.4\u00a0% important). St. John's wort was the medicinal plant with most interactions (92.6\u00a0% were considered important). The rest were: important (ginseng-imatinib, methotrexate-cola and tobacco-erlotinib and tobacco-pomalidomide) and moderate (caffeine-vemurafenib/medroxyprogesterone, medroxyprogesterone-ruxolitinib/St. John's wort, garlic-anagrelide and ginseng-procarbazine).", "Twenty-six interactions (61.5\u00a0% important). Grapefruit had most interactions (82.4\u00a0% were considered important). The rest were: important (alcohol-procarbazine) and moderate (dairy-estramustine, methotrexate-ethanol, procarbazine-tyramine, vitamin A-tretinoin/bexarotene and grapefruit-bexarotene/etoposide/sunitinib).", "A review of interactions of medicinal plants and food should be taken into account in the management of OAAs, since more than half have interactions with MPs and food, of which 70.3\u00a0% are considered important. The most relevant are HSJ, grapefruit, ginseng and tobacco. This review is intended to serve as a support to all healthcare professionals at the time of prescribing or dispensing OAAs."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacy Department, Gregorio Mara\u00f1\u00f3n General University Hospital, Madrid, Spain."}], "LastName": "Collado-Borrell", "ForeName": "Roberto", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacy Department, Gregorio Mara\u00f1\u00f3n General University Hospital, Madrid, Spain. vicente.escudero@salud.madrid.org."}], "LastName": "Escudero-Vilaplana", "ForeName": "Vicente", "Initials": "V"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacy Department, Gregorio Mara\u00f1\u00f3n General University Hospital, Madrid, Spain."}], "LastName": "Romero-Jim\u00e9nez", "ForeName": "Rosa", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Complutense University of Madrid, Madrid, Spain."}], "LastName": "Iglesias-Peinado", "ForeName": "Irene", "Initials": "I"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacy Department, Gregorio Mara\u00f1\u00f3n General University Hospital, Madrid, Spain."}], "LastName": "Herranz-Alonso", "ForeName": "Ana", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacy Department, Gregorio Mara\u00f1\u00f3n General University Hospital, Madrid, Spain."}], "LastName": "Sanjurjo-S\u00e1ez", "ForeName": "Mar\u00eda", "Initials": "M"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "J Cancer Res Clin Oncol", "NlmUniqueID": "7902060", "ISSNLinking": "0171-5216"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Administration, Oral"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Food-Drug Interactions"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Plants, Edible"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "J Diet Suppl. 2012 Jun;9(2):90-5", "ArticleIdList": ["22607644"]}, {"Citation": "Expert Opin Drug Saf. 2013 May;12(3):403-20", "ArticleIdList": ["23586848"]}, {"Citation": "Pharmacotherapy. 2004 Nov;24(11):1508-14", "ArticleIdList": ["15537555"]}, {"Citation": "Sci Pharm. 2010;78(3):473-81", "ArticleIdList": ["20936048"]}, {"Citation": "Ann Oncol. 2005 Apr;16(4):655-63", "ArticleIdList": ["15699021"]}, {"Citation": "Phytomedicine. 2004 Feb;11(2-3):98-104", "ArticleIdList": ["15070158"]}, {"Citation": "J Clin Oncol. 1997 Jan;15(1):110-5", "ArticleIdList": ["8996131"]}, {"Citation": "Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):359-77", "ArticleIdList": ["24387348"]}, {"Citation": "Public Health Nutr. 2009 Sep;12(9):1576-9", "ArticleIdList": ["18986589"]}, {"Citation": "Drug Metab Pharmacokinet. 2011;26(2):201-5", "ArticleIdList": ["21178302"]}, {"Citation": "MedGenMed. 2006 May 30;8(2):61", "ArticleIdList": ["16926800"]}, {"Citation": "Pharmacol Ther. 2013 Apr;138(1):103-41", "ArticleIdList": ["23333322"]}, {"Citation": "J Clin Pharmacol. 2010 Feb;50(2):188-94", "ArticleIdList": ["19948946"]}, {"Citation": "AAPS J. 2009 Sep;11(3):481-94", "ArticleIdList": ["19590965"]}, {"Citation": "Nephrology (Carlton). 2008 Jun;13(4):337-47", "ArticleIdList": ["18363644"]}, {"Citation": "Oncologist. 2006 Jul-Aug;11(7):732-41", "ArticleIdList": ["16880232"]}, {"Citation": "J Manag Care Pharm. 2006 Sep;12 (7):570-7", "ArticleIdList": ["16981802"]}, {"Citation": "Curr Opin Pharmacol. 2006 Aug;6(4):350-4", "ArticleIdList": ["16690355"]}, {"Citation": "Cancer Res. 2008 Oct 1;68(19):8031-8", "ArticleIdList": ["18829561"]}, {"Citation": "Drug Metabol Drug Interact. 2009;24(1):17-35", "ArticleIdList": ["19353999"]}, {"Citation": "Clin Pharmacol Ther. 2004 Oct;76(4):323-9", "ArticleIdList": ["15470331"]}, {"Citation": "J Natl Compr Canc Netw. 2008 Mar;6 Suppl 3:S1-14", "ArticleIdList": ["18377852"]}, {"Citation": "Cancer Chemother Pharmacol. 2011 Mar;67(3):695-703", "ArticleIdList": ["20512335"]}, {"Citation": "Biochem Pharmacol. 2008 Mar 15;75(6):1302-12", "ArticleIdList": ["18234154"]}, {"Citation": "Nutr Cancer. 2014;66(5):757-73", "ArticleIdList": ["24820444"]}, {"Citation": "Ann Pharmacother. 2010 May;44(5):926-8", "ArticleIdList": ["20332334"]}, {"Citation": "J Steroid Biochem Mol Biol. 2003 Mar;84(4):463-8", "ArticleIdList": ["12732291"]}, {"Citation": "Hosp Pharm. 2015 Feb;50(2):91-2", "ArticleIdList": ["25717200"]}, {"Citation": "J Pharm Sci. 2015 Jan;104(1):266-75", "ArticleIdList": ["25418056"]}, {"Citation": "Leuk Lymphoma. 2013 May;54(5):1094-6", "ArticleIdList": ["23061529"]}, {"Citation": "J Altern Complement Med. 2002 Jun;8(3):293-308", "ArticleIdList": ["12165187"]}, {"Citation": "Lancet Oncol. 2011 Dec;12(13):1249-57", "ArticleIdList": ["21741307"]}, {"Citation": "Pharm World Sci. 2003 Jun;25(3):94-7", "ArticleIdList": ["12840961"]}, {"Citation": "Toxicol Appl Pharmacol. 2012 Aug 15;263(1):39-43", "ArticleIdList": ["22699020"]}, {"Citation": "Am J Epidemiol. 2006 Apr 1;163(7):645-53", "ArticleIdList": ["16484447"]}]}], "History": [{"Year": "2015", "Month": "10", "Day": "26"}, {"Year": "2016", "Month": "6", "Day": "9"}, {"Year": "2016", "Month": "6", "Day": "19", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "6", "Day": "19", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "2", "Day": "9", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["27316629", "10.1007/s00432-016-2190-8", "10.1007/s00432-016-2190-8"]}}]}